Obsessive Compulsive Disorder Therapeutics Market to Grow at 4.8% up to 2019, States GlobalData30 May 2012 • by Natalie Aster
The global Obsessive Compulsive Disorder (OCD) therapeutics market was worth $317m in 2011 and will grow at a CAGR of 4.8% to reach $461m by 2019. The OCD therapeutics market showed a low CAGR growth of 1.1% from 2006 to 2011 mainly due to the patent expiries of Zoloft (sertraline) in 2006, and Paxil (paroxetine) in 2007 in the US, 2006 in Europe and 2011 in Japan.
According to the report “Obsessive Compulsive Disorder (OCD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019” by GlobalData, The OCD therapeutics market is a generic market with a low cost of therapy. No pipeline drugs are expected to be launched during the forecast period. The low steady growth of the market until 2019 is primarily attributed to an increasing public awareness of the disorder.
However, the low diagnosis rate and the presence of non-pharmacological therapies such as psychosocial therapy will act as barriers to the market growth of the OCD therapeutics market.
Obsessive Compulsive Disorder (OCD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Published: April, 2012
Price: US$ 3.995,00
The pipeline for OCD therapeutics consists of nine molecules in various stages of development. The pipeline is said to be weak primarily because there are few molecules in the pipeline. The other factor that contributes to the weak pipeline is that most trials are university or institute sponsored; these are small clinical trials which are being conducted to develop a second line of therapy for OCD patients who do not responded to the first line of treatment with SSRIs. The company sponsored products are in early stages of development (Phase II and Pre-clinical stage). There seems to be little research by pharmaceutical companies into the development of drugs for the treatment of OCD. The current pipeline lacks molecules with a novel mechanism of action that can shift the treatment paradigm for OCD. There is only one molecule in Phase III of clinical development, Gamunex which is a first-in class molecule. There are six molecules in Phase II of the OCD pipeline. PNB05 is the only molecule in the pre-clinical stage and CR 5542 Series is the only molecule in the discovery stage.
More information can be found in the report “Obsessive Compulsive Disorder (OCD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019” by GlobalData.
To order the report or ask for sample pages contact email@example.com